Journal of Drugs in Dermatology articles from June 2007

Journal of Drugs in Dermatology archives from June 2007

Letter from the guest editor.(Editorial)
June 1, 2007... Over the past several years, I have dedicated a significant amount of time and energy to educational and research endeavors in dermatology, including several publications about acne vulgaris and rosacea. I have had the opportunity to work...

Adverse effects from intravascular injection of hyaluronic acid.(LETTERS TO THE EDITOR)(Letter to the editor)
June 1, 2007... In your March issue case report of "Delayed Presentation of Impending Necrosis following Soft Tissue Augmentation with Hyaluronic Acid and Successful Management with Hyaluronidase," basic mechanisms of hyaluronic acid (HA) induced vascular...

The Propionibacterium acnes genome: from the laboratory to the clinic.
June 1, 2007... Abstract The genome of Propionibacterium acnes, the microbe presumed to be at least partially etiologic for the development of acne, has recently been decoded. The genome supports long-standing concepts regarding acne pathogenesis, but...

Pediatric acne: Clinical presentations, evaluation, and management.
June 1, 2007... Abstract Acne vulgaris can be easy to diagnose yet difficult to evaluate and manage, especially when it presents in infancy and childhood. The differential diagnosis of acne varies by age and, in some cases, may warrant a work-up in order...

A closer look at truncal acne vulgaris: prevalence, severity, and clinical significance.(Statistical data)
June 1, 2007... Abstract Data is very limited on the demographics, epidemiology, grading, and management of truncal acne vulgaris. In this study completed in 5 cities across the US, 696 patients were assessed to evaluate the frequency and severity of...

Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris.(Clinical report)
June 1, 2007... Abstract Clindamycin phosphate 1.2% and tretinoin 0.025% gel (CLIN/RA gel [ZIANA[TM] Gel]) is a novel topical combination agent approved by the FDA for the treatment of acne vulgaris in patients 12 years of age or older. A solution of...

Study results of benzoyl peroxide 5%/clindamycin 1% topical gel, adapalene 0.1% gel, and use in combination for acne vulgaris.(Clinical report)
June 1, 2007... Abstract Combination therapy is the standard of care in the management of acne vulgaris. It is essential to treat as many aspects of acne pathogenesis as possible. Due to increasing insensitivity of Propionibacterium acnes to antibiotics,...

A comparative review of the efficacy and tolerability of retinoid-containing combination regimens for the treatment of acne vulgaris.(Clinical report)
June 1, 2007... Abstract Many physicians regularly prescribe combination therapy involving a retinoid for their acne patients. The most common retinoid-containing regimens include either oral antibiotics or topical benzoyl peroxide and antibiotic...

Tolerability comparison of adapalene gel, 0.3% versus tazarotene cream, 0.05% in subjects with healthy skin.(Clinical report)
June 1, 2007... Abstract Background: Topical retinoids, including adapalene and tazarotene, are a primary treatment choice for patients with acne. Adapalene is currently marketed in a 0.1% concentration in gel and cream formulation. A new gel containing a...

Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, USP monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea.(Clinical report)
June 1, 2007... Abstract Research into the pathophysiology of rosacea suggests a central role for inflammatory mediators such as nitric oxide (NO), reactive oxygen species (ROS), and matrix metalloproteinases (MMPs). Effective treatments for rosacea,...

Efalizumab-associated lymphoproliferative disease.(CASE REPORTS)
June 1, 2007... Abstract Efalizumab is an immunosuppressive agent that has been approved for the treatment of psoriasis. There has been mounting evidence that efalizumab may be associated with lymphoma/malignancy development. To our knowledge, this is the...

Clearance of lentigines in Japanese men with the long-pulsed Alexandrite laser.(CASE REPORTS)
June 1, 2007... Abstract Benign pigmented lesions can be effectively treated with multiple modalities including lasers. The treatment of pigmented lesions in phototype IV skin is more complicated and challenging given the risk of pigmentation changes and...

Updates & perspectives on management of common dermatologic disorders.(LIT REVIEW)(Clinical report)
June 1, 2007... Acne Vulgaris Azelaic Acid 15% Gel for Acne Vulgaris Azelaic acid (AZA) 15% gel and 20% cream are FDA-approved for the treatment of acne vulgaris and rosacea, respectively. As the cutaneous bioavailability of AZA is 8-fold greater...

Vitiligo--new associations suggest new therapeutic approaches.(NEWS, VIEWS, AND REVIEWS)(Disease/Disorder overview)
June 1, 2007... Vitiligo is a common disease of acquired hypomelanosis due to a reduced number or function of cutaneous melanocytes. Affecting around 1% of the global population, vitiligo classically presents with well-demarcated patches of skin and hair...

Topical eflornithine for unwanted hair--does it work? Will it prevent cancer?(NEWS, VIEWS, AND REVIEWS)
June 1, 2007... For women, unwanted facial hair can significantly impact their quality of life. (1) Traditionally this common condition is treated with mechanical or chemical depilation, shaving, or electrolysis. When appropriate hormonal therapies can be...

FDA grants tentative approval for Ciclopirox.(PIPELINE PREVIEWS)(Food and Drug Administration)(Brief article)
June 1, 2007... Hi-Tech Pharmacal Co, Inc recently announced that it has received tentative approval from the FDA for Ciclopirox topical solution, 8%. This solution is the generic equivalent of Penlac[R] topical solution 8%, which is manufactured by Dermik...

Altabax approved by the FDA.(PIPELINE PREVIEWS)(Food and Drug Administration)(Brief article)
June 1, 2007... GlaxoSmithKline recently announced that the FDA has granted approval for its antibacterial Altabax[TM] (retapamulin ointment), 1% for the treatment of impetigo caused by Staphylococcus aureus or Streptococcus pyogenes. Altabax is approved for...

FDA approves Loratadine.(PIPELINE PREVIEWS)(Food and Drug Administration)(Brief article)
June 1, 2007... Ohm Laboratories Inc, a subsidiary of Ranbaxy Laboratories Limited, recently announced that its Loratadine Orally Disintegrating Tablets, 10mg, has been granted approval by the FDA. This product is bioequivalent to Claritin[R] Reditabs[R],...

Phase III trial of Genasense in melanoma.(PIPELINE PREVIEWS)(Brief article)
June 1, 2007... A randomized, controlled phase III trial of Genasense[R] (oblimersen sodium) injection in patients with advanced melanoma will be conducted by Genta Incorporated with patient enrollment to begin this summer. Genasense has been granted Orphan...

Etanercept therapy in the treatment of psoriasis.(PIPELINE PREVIEWS)(Brief article)
June 1, 2007... A recent randomized, open-label trial evaluated the effectiveness and safety of continuous versus interrupted etanercept therapy for the treatment of psoriasis. All patients were treated with continuous etanercept 50 mg twice weekly for 12...

DX-88 for treatment of hereditary angioedema.(PIPELINE PREVIEWS)(Brief article)
June 1, 2007... Dyax Corporation recently announced the initiation of a phase III trial, EDEMA4 for DX-88 (ecallantide). DX-88 is a recombinant, plasma kallikrein inhibitor that will be evaluated for the treatment of acute attacks of hereditary angioedema....

Phase IIb trials of NP-1 for neuropathic pain.(PIPELINE PREVIEWS)(Brief article)
June 1, 2007... EpiCept Corporation recently announced the initiation of 2 phase IIb trials of NP-1 for neuropathic pain. NP-1 is a topical prescription analgesic cream for use in the long-term relief of pain from peripheral neuropathies such as post-herpetic...

Dermatology meetings in June.(Brief article)(Calendar)
June 1, 2007... 6/8-6/11 11th World Congress on Cancers of the Skin Amsterdam, Netherlands http://wccs2007.ics-online.com 6/15-6/17 Dermatology Review Minneapolis, MN www.aad.org 6/15-6/17 Georgia Society of...

Effect of bosentan on skin fibrosis in patients with systemic sclerosis.(CLINICAL TRIAL REVIEW)(Brief article)
June 1, 2007... Sponsored by Heinrich-Heine University, Duesseldorf. The purpose of this study is to evaluate the effect of bosentan treatment on skin fibrosis and its functionality in patients with systemic sclerosis. compiled by Hillary Johnson MD PhD...

Sunless tanning products as a substitute for sunbathing in healthy participants.(CLINICAL TRIAL REVIEW)(Brief article)
June 1, 2007... Sponsors and Collaborators: UMASS Memorial Cancer Center--University Campus and National Cancer Institute (NCI). This phase I/II trial is studying attitudes about the use of sunless tanning products and how well sunless tanning products work as...

Hematopoietic stem cell support in patients with autoimmune bullous skin disorders.(CLINICAL TRIAL REVIEW)(Brief article)
June 1, 2007... Sponsored by Northwestern University. This study is designed to examine whether treating patients with a high dose of cyclophosphamide together with antithymocyte globulin, followed by a return of the previously collected special blood cells...

Peritumoral injection of immature dendritic cells to irradiated skin metastases of solid tumors.(CLINICAL TRIAL REVIEW)(Brief article)
June 1, 2007... Sponsored by Hadassah Medical Organization. The long-term objective of this study is to develop a therapeutic approach for the treatment of cancer in general, and melanoma in particular, based on immunotherapy, using a combination of local...

Leptin to treat lipodystrophy.(CLINICAL TRIAL REVIEW)(Brief article)
June 1, 2007... Sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This study will evaluate the safety and effectiveness of leptin replacement therapy in patients with lipodystrophy (also called lipoatrophy). Condition...

The effect of a controlled daily skin care regimen on retinoic acid tolerance.(CLINICAL TRIAL REVIEW)(Brief article)
June 1, 2007... Sponsors and Collaborators: University of Michigan and Unilever. The purpose of this study is to examine whether a daily skin care regimen comprised of an ultra mild cleanser and an effective moisturizer can help improve tolerance to topical...

LMB-2 immunotoxin and vaccine therapy in treating patients with metastatic melanoma that cannot be removed by surgery.(CLINICAL TRIAL REVIEW)(Brief article)
June 1, 2007... Sponsored by National Cancer Institute (NCI). This phase II trial is studying how well giving LMB-2 immunotoxin together with vaccine therapy, using vaccines made from peptides, works in treating patients with metastatic melanoma that cannot be...

Chemotherapy and total-body irradiation followed by autologous lymphocyte infusion, aldesleukin, and autologous stem cell transplant in treating patients with metastatic melanoma.(CLINICAL TRIAL REVIEW)(Brief article)
June 1, 2007... Sponsored by National Cancer Institute (NCI). This phase II trial is studying how well chemotherapy and total-body irradiation followed by autologous lymphocyte infusion, aldesleukin, and autologous stem cell transplant work in treating...

Chemotherapy followed by autologous natural killer cells and aldesleukin in treating patients with metastatic melanoma or kidney cancer.(CLINICAL TRIAL REVIEW)(Brief article)
June 1, 2007... Sponsored by National Cancer Institute (NCI). This phase II trial is studying how well giving chemotherapy followed by autologous natural killer cells and aldesleukin, works in treating patients with metastatic melanoma or kidney cancer. ...

Molecular mechanisms of helium-neon laser on melanocyte regeneration in skin equivalent vitiligo model.(CLINICAL TRIAL REVIEW)(Brief article)
June 1, 2007... Sponsored by National Taiwan University Hospital. This current 3-year proposal aims to clarify the mechanisms of melanocyte destruction and regeneration in vitiligo lesions using both traditional cell culture and skin equivalent model...

Evaluation of pigmented skin lesions with MelaFind system.(CLINICAL TRIAL REVIEW)(Brief article)
June 1, 2007... Sponsored by Electro-Optical Sciences. The purpose of this clinical trial is to demonstrate that MelaFind[R], a new instrument that uses machine vision for noninvasive early detection of cutaneous pigmented malignant melanoma, is safe and...

Mometasone furoate in preventing radiation dermatitis in patients undergoing radiation therapy to the breast or chest wall for invasive breast cancer or ductal carcinoma in situ.(CLINICAL TRIAL REVIEW)(Brief article)
June 1, 2007... Sponsors and Collaborators: North Central Cancer Treatment Group and National Cancer Institute (NCI). This randomized phase III trial is studying mometasone furoate to see how well it works compared to a placebo in preventing radiation...

Etanercept for treatment of hidradenitis.(CLINICAL TRIAL REVIEW)(Brief article)
June 1, 2007... Sponsored by University of Pennsylvania. The purpose of this study is to determine whether etanercept is safe and effective for the treatment of hidradenitis. Another purpose of this study is to determine the impact of etanercept treatment of...

Treatment of melasma with Jessner's solution versus trichloroacetic acid.(CLINICAL TRIAL REVIEW)(Brief article)
June 1, 2007... Sponsored by Emory University. The purpose of this study is determine if there is a difference in the effectiveness of Jessner's solution and trichloroacetic acid in the treatment of melasma. Condition Intervention ...

Monoclonal antibody therapy in treating patients with ovarian epithelial cancer, melanoma, acute myeloid leukemia, myelodysplastic syndrome, or nonsmall cell lung cancer.(CLINICAL TRIAL REVIEW)(Brief article)
June 1, 2007... Sponsors and Collaborators: Dana-Farber Cancer Institute and National Cancer Institute (NCI). This phase I trial is studying the side effects of monoclonal antibody therapy in treating patients with ovarian epithelial cancer, melanoma, acute...

A small clinical study: photodynamic therapy to treat hidradenitis suppurativa.(CLINICAL TRIAL REVIEW)(Brief article)
June 1, 2007... Sponsors and Collaborators: University of Kansas and DUSA Pharmaceuticals. This study will investigate the efficacy of photodynamic therapy, which is the therapeutic use of photochemical reactions, in treating hidradenitis suppurativa, a...

Topical 5-ALA photodynamic therapy for the treatment of verruca vulgaris.(CLINICAL TRIAL REVIEW)(aminolevulinic acid)(Brief article)
June 1, 2007... Sponsored by National Taiwan University Hospital. The purpose of this clinical trial is to develop topical aminolevulinic acid photodynamic therapy as an alternative treatment for warts but without the unwanted side effects of pain and burning....

Celecoxib in managing pain, weight loss, and weakness in patients with advanced cancer.(CLINICAL TRIAL REVIEW)(Brief article)
June 1, 2007... Sponsors and Collaborators: Eastern Cooperative Oncology Group and National Cancer Institute (NCI). This randomized clinical trial is studying celecoxib to see how well it works in managing pain, weight loss, and weakness in patients with...

The science of next generation anti-aging cosmeceuticals.(Letter to the editor)
June 1, 2007... As the number of baby-boomers in the population continues to expand, patients and consumers are faced with ever increasing choices of skin care products available both in the physician's office as well as in the over-the-counter setting. It is...

The use of antisense strategy to modulate human melanogenesis.
June 1, 2007... Abstract Background and Objectives: Skin without significant dyschromia is an aesthetic goal of people worldwide. Current options for lightening skin could have significant drawbacks. The antisense strategy may be a viable alternative. The...

In vivo skin antioxidant effect of a new combination based on a specific Vitis vinifera shoot extract and a biotechnological extract.
June 1, 2007... Abstract Background and Objectives: Ultraviolet (UV) light produces reactive oxygen species (ROS) in skin, which accelerate aging by damaging DNA, proteins, lipids, and other cellular constituents. The aims of this study were to 1)...

Enhancing cell longevity for cosmetic application: a complementary approach.
June 1, 2007... Abstract Background and Objectives: Cell longevity is linked to sirtuins (silent information regulators), which belong to a family of enzymes implicated in gene silencing, apoptosis, fatty acid metabolism, and regulation of cellular life...

Hydrating skin by stimulating biosynthesis of aquaporins.
June 1, 2007... Abstract Aquaporins (AQPs) are proteins that facilitate the transport of water across cell membranes. AQP3 expression is related to the expressions of other epidermal proteins involved in water maintenance (ie, CD44, claudin-1, and...

Modulation of gene expression as a new skin anti-aging strategy.(Clinical report)
June 1, 2007... Abstract Backround/Objectives: The signs of aging may originate from natural processes or from exposure to the sun, wind, or other environmental factors. To evaluate the anti-aging effects of potential agents researchers must first...